thalidomide has been researched along with Depression in 16 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Randomized, controlled trials demonstrated efficacy and safety of apremilast for moderate-to-severe plaque psoriasis and psoriatic arthritis." | 9.24 | Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). ( Cather, JC; Chen, R; Crowley, J; Day, RM; Ferrándiz, C; Goncalves, J; Joly, P; Papp, KA; Peris, K; Shah, K; Thaçi, D, 2017) |
| "To quantify the risk of incident treated anxiety, depression and mixed anxiety + depression in users of apremilast compared with users of other treatments for psoriasis and PsA." | 7.96 | The risk of treated anxiety and treated depression among patients with psoriasis and psoriatic arthritis treated with apremilast compared to biologics, DMARDs and corticosteroids: a cohort study in the United States MarketScan database. ( Hagberg, KW; Jick, S; Persson, R; Vasilakis-Scaramozza, C, 2020) |
| "Treatment with apremilast was well tolerated, with generally mild gastrointestinal complaints, which occurred early in the course of the treatment and resolved over time, and there was no requirement for laboratory test monitoring." | 6.52 | Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast. ( Gooderham, M; Papp, K, 2015) |
| "Lenalidomide was well tolerated in intensively pretreated and elderly MM patients, including those with RI." | 5.38 | Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal. ( Engelhardt, M; Ihorst, G; Kleber, M; Koch, B; Udi, J; Wäsch, R, 2012) |
| "Randomized, controlled trials demonstrated efficacy and safety of apremilast for moderate-to-severe plaque psoriasis and psoriatic arthritis." | 5.24 | Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). ( Cather, JC; Chen, R; Crowley, J; Day, RM; Ferrándiz, C; Goncalves, J; Joly, P; Papp, KA; Peris, K; Shah, K; Thaçi, D, 2017) |
| "To quantify the risk of incident treated anxiety, depression and mixed anxiety + depression in users of apremilast compared with users of other treatments for psoriasis and PsA." | 3.96 | The risk of treated anxiety and treated depression among patients with psoriasis and psoriatic arthritis treated with apremilast compared to biologics, DMARDs and corticosteroids: a cohort study in the United States MarketScan database. ( Hagberg, KW; Jick, S; Persson, R; Vasilakis-Scaramozza, C, 2020) |
| "As Thalidomide survivors reach their mid-50's they are experiencing a wide range of secondary health problems, in particular musculoskeletal problems, and depression and anxiety, with multimorbidity a growing issue." | 3.91 | The health and quality of life of Thalidomide survivors as they age - Evidence from a UK survey. ( Atkin, K; Glendinning, C; Newbronner, E; Wadman, R, 2019) |
| "Treatment with apremilast was well tolerated, with generally mild gastrointestinal complaints, which occurred early in the course of the treatment and resolved over time, and there was no requirement for laboratory test monitoring." | 2.52 | Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast. ( Gooderham, M; Papp, K, 2015) |
| "Thalidomide is a sedative/hypnotic agent that is currently used to treat patients suffering from multiple myeloma, myelodysplastic syndromes and erythema nodosum leprosum." | 1.51 | Involvement of the nitric oxide pathway in the anti-depressant-like effects of thalidomide in mice. ( Dehpour, AR; Gharedaghi, A; Norouzi-Javidan, A; Rostamian, A, 2019) |
| "Mechanical hyperalgesia was evaluated every 3 days by von Frey filaments and depressive-like behavior was assessed at the end of day 15, using the tail suspension test (TST) and the forced swimming test (FST)." | 1.42 | Thalidomide reduces mechanical hyperalgesia and depressive-like behavior induced by peripheral nerve crush in mice. ( Borges, FR; Cremonese, RP; da Silva, MD; Luiz-Cerutti, M; Macedo-Júnior, SJ; Martins, DF; Nascimento, FP; Rodrigues, AL; Santos, AR, 2015) |
| "Lenalidomide was well tolerated in intensively pretreated and elderly MM patients, including those with RI." | 1.38 | Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal. ( Engelhardt, M; Ihorst, G; Kleber, M; Koch, B; Udi, J; Wäsch, R, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (12.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (81.25) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Vasilakis-Scaramozza, C | 1 |
| Persson, R | 1 |
| Hagberg, KW | 1 |
| Jick, S | 1 |
| Crowley, J | 1 |
| Thaçi, D | 1 |
| Joly, P | 1 |
| Peris, K | 1 |
| Papp, KA | 1 |
| Goncalves, J | 1 |
| Day, RM | 1 |
| Chen, R | 1 |
| Shah, K | 1 |
| Ferrándiz, C | 1 |
| Cather, JC | 1 |
| Schmutz, JL | 2 |
| Newbronner, E | 1 |
| Glendinning, C | 1 |
| Atkin, K | 1 |
| Wadman, R | 1 |
| Rostamian, A | 1 |
| Gharedaghi, A | 1 |
| Norouzi-Javidan, A | 1 |
| Dehpour, AR | 1 |
| Souza, LC | 1 |
| Filho, CB | 1 |
| Fabbro, LD | 1 |
| de Gomes, MG | 1 |
| Goes, AT | 1 |
| Jesse, CR | 1 |
| Fraser, K | 1 |
| Ismail, B | 1 |
| Aboul-Fotouh, S | 1 |
| Mansour, AA | 1 |
| Shehata, HH | 1 |
| Salman, MI | 1 |
| Ibrahim, EA | 1 |
| Hassan, OA | 1 |
| Abdel-tawab, AM | 1 |
| Nascimento, FP | 1 |
| Macedo-Júnior, SJ | 1 |
| Borges, FR | 1 |
| Cremonese, RP | 1 |
| da Silva, MD | 1 |
| Luiz-Cerutti, M | 1 |
| Martins, DF | 1 |
| Rodrigues, AL | 2 |
| Santos, AR | 2 |
| Gooderham, M | 1 |
| Papp, K | 1 |
| Kaster, MP | 1 |
| Gadotti, VM | 1 |
| Calixto, JB | 1 |
| Kleber, M | 1 |
| Ihorst, G | 1 |
| Udi, J | 1 |
| Koch, B | 1 |
| Wäsch, R | 1 |
| Engelhardt, M | 1 |
| SIMON, A | 1 |
| Gibbels, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study to Evaluate the Efficacy and Safety of Apremilast in Patients of Chronic and Recurrent Erythema Nodosum Leprosum[NCT04822909] | Phase 4 | 10 participants (Actual) | Interventional | 2019-09-15 | Completed | ||
| Efficacy and Safety of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis[NCT06032858] | Phase 4 | 30 participants (Actual) | Interventional | 2022-03-06 | Completed | ||
| Molecular Effects of Apremilast in the Synovium of Psoriatic Arthritis Patients (MEAS Study)[NCT04645420] | 19 participants (Actual) | Interventional | 2020-11-12 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for thalidomide and Depression
| Article | Year |
|---|---|
Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast.
Topics: Clinical Trials, Phase II as Topic; Depression; Drug Interactions; Humans; Phosphodiesterase 4 Inhib | 2015 |
1 trial available for thalidomide and Depression
| Article | Year |
|---|---|
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Depression; Diarrhea; Femal | 2017 |
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Depression; Diarrhea; Femal | 2017 |
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Depression; Diarrhea; Femal | 2017 |
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Depression; Diarrhea; Femal | 2017 |
14 other studies available for thalidomide and Depression
| Article | Year |
|---|---|
The risk of treated anxiety and treated depression among patients with psoriasis and psoriatic arthritis treated with apremilast compared to biologics, DMARDs and corticosteroids: a cohort study in the United States MarketScan database.
Topics: Adrenal Cortex Hormones; Antirheumatic Agents; Anxiety; Arthritis, Psoriatic; Biological Products; C | 2020 |
The good, the bad and the ugly.
Topics: Contraceptive Agents; Depression; Electroconvulsive Therapy; Female; History, 20th Century; History, | 2017 |
[Apremilast withdrawals more frequent in standard practice than in clinical trials].
Topics: Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Depression; Female; Humans; Male; | 2018 |
The health and quality of life of Thalidomide survivors as they age - Evidence from a UK survey.
Topics: Adult; Aging; Anxiety; Depression; Employment; Female; Humans; Hypnotics and Sedatives; Male; Middle | 2019 |
Involvement of the nitric oxide pathway in the anti-depressant-like effects of thalidomide in mice.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Humans; Locomotion; Metabolic Ne | 2019 |
Depressive-like behaviour induced by an intracerebroventricular injection of streptozotocin in mice: the protective effect of fluoxetine, antitumour necrosis factor-α and thalidomide therapies.
Topics: Animals; Antibodies, Neutralizing; Antidepressive Agents; Behavior, Animal; Depression; Dietary Sucr | 2013 |
72nd annual meeting of the American Academy of Dermatology.
Topics: Antifungal Agents; Attention Deficit Disorder with Hyperactivity; Boron Compounds; Botulinum Toxins, | 2014 |
Behavioural, metabolic, and endothelial effects of the TNF-α suppressor thalidomide on rats subjected to chronic mild stress and fed an atherogenic diet.
Topics: Animals; Antidepressive Agents, Tricyclic; Aorta, Thoracic; Atherosclerosis; Chronic Disease; Depres | 2014 |
Thalidomide reduces mechanical hyperalgesia and depressive-like behavior induced by peripheral nerve crush in mice.
Topics: Animals; Depression; Hindlimb Suspension; Hyperalgesia; Male; Mice; Nerve Crush; Pain Measurement; P | 2015 |
[Apremilast: Beware of suicidal ideation and behaviour].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Depression; France; Humans; Prevalence; Psoriasis; Risk Fac | 2017 |
Depressive-like behavior induced by tumor necrosis factor-α in mice.
Topics: Analysis of Variance; Animals; Antibodies; Antidepressive Agents; Depression; Disease Models, Animal | 2012 |
Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Dep | 2012 |
PSYCHIATRIC INDICATIONS FOR THERAPEUTIC ABORTION AND STERILIZATION.
Topics: Abnormalities, Drug-Induced; Abortion, Induced; Abortion, Therapeutic; Depression; Family; Female; H | 1964 |
[Toxic injuries in thalidomide medication].
Topics: Adult; Depression; Female; Humans; Male; Middle Aged; Polyneuropathies; Pregnancy; Pregnancy Complic | 1967 |